 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced the authorization of its Clinical Trial Application CTA by the United Kingdom Medicines and Healthcare products Regulatory Agency MHRA to initiate a Phase 12a study ADMIRAL of STK-001 for the treatment of Dravet syndrome. STK-001, a proprietary antisen 